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around pregnancy and childbirth (cocooning) could further protect infants. In this 
study cost-effectiveness of cocooning was estimated for The Netherlands. METHODS: 
A decision tree model was developed with a birth cohort and cohort of parents. The 
beneﬁts of pertussis immunization take the direct effect on parents and the indirect 
effect of a reduced transmission to infants into account. The incidence rate based on 
reported cases in The Netherlands has been corrected to take symptomatic unreported 
cases into account. In the sensitivity analysis the impact of the underreporting factor 
on the ICER (Incremental Cost-Effectiveness Ratio) was analyzed. The robustness of 
the estimated ICER was estimated by varying vaccine efﬁcacy, vaccine costs, QALY 
(Quality-Adjusted Life-Year) estimates and indirect beneﬁts. RESULTS: Implementa-
tion of the cocooning immunization strategy is estimated to prevent 57 infant pertussis 
cases per year. From the payer’s perspective, the ICER is estimated at a4,500/QALY 
in the base-case. Sensitivity analysis revealed that the ICER was hardly sensitive to 
vaccine price, indirect beneﬁts and vaccine efﬁcacy. The ICER was however sensitive 
to the underreporting factor, quality of life and cost assumptions for these unreported 
cases. From the societal perspective, the cocooning immunization strategy is estimated 
as cost saving. By decreasing the underreporting factor or QALY losses and costs in 
unreported cases no cost-savings were found anymore, yet the cocooning immuniza-
tion remained highly cost-effective. CONCLUSIONS: The addition of a cocooning 
immunization strategy to the current pertussis immunization programme is likely to 
be cost-effective or even cost-saving from a societal perspective. However the ICER is 
sensitive to the underreporting factor, QALY estimates and costs assumptions in the 
unreported pertussis cases.
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COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS 
PODOPHYLLOTOXIN IN TREATMENT OF GENITAL/PERIANAL WARTS 
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OBJECTIVES: To conduct a cost-effectiveness analysis (CEA) of imiquimod versus 
podophyllotoxin as standard regimen in treatment of genital/perianal warts in Poland. 
METHODS: Our analysis was carried out using a decision model based on the clinical 
effects of imiquimod and podophyllotoxin, obtained from prospective clinical trials. 
Population was deﬁned as adult patients with genital/perianal warts. Total clearing 
warts was assessed as health outcome. Direct medical costs of the analyzed therapies 
were estimated from the perspective of both payers in Poland (National Health Fund 
and patient). Costs of medication and clinic visits were included. Time horizon of the 
analysis was 28 weeks, as during the clinical trial for imiquimod. We assumed the 
mean time of treatment at 13.65 weeks (once a day 3x/week regimen) for imiquimod 
and 4 weeks for podophyllotoxin. Costs and effects were not discounted. RESULTS: 
Probability of total clearing warts was 0.429 for patients treated with imiquimod and 
0.196, for podophyllotoxin teatment. Total costs of imiquimod therapy were esti-
mated at 1121.34 PLN and costs of podophyllotoxin therapy at 218.35 PLN. Incre-
mental cost-effectiveness ratio (ICER) for the comparison of imiquimod versus 
podophyllotoxin was 3865 PLN per gained total clearing warts. CONCLUSIONS: 
Imiquimod is more effective and more expensive than podophyllotoxin in treatment 
of genital/perianal warts. ICER value is below the acceptable threshold, therefore 
imiquimod therapy is considered as cost-effective treatment in Poland.
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OBJECTIVES: To estimate the health outcomes of vaccination with the new 10-valent 
pneumococcal non-typeable Haemophilus inﬂuenzae protein-D conjugate vaccine 
(PH¡D-CV) compared with no vaccination. METHODS: A cross-sectional population-
based model was used to estimate the impact of vaccination over 1-year at vaccine 
steady-state and to perform an incremental cost-effectiveness analysis, comparing 31 
dose vaccination schedule of PH¡D-CV vs no vaccination. Universal massive vaccina-
tion (UMV) for pneumococcal disease is currently not compulsory according to the 
National Vaccination Calendar in Spain. The analysis was performed from the 
National Health System perspective. Input data were obtained from the Ministry of 
Health public database and published regional studies, and was completed by expert 
opinion to validate model assumptions on the vaccination effects of herd-protection 
for invasive disease, serotype replacement, serotype cross-protection and resource use. 
The main clinical outcomes measured were invasive pneumococcal disease (meningitis 
and bacteraemia/sepsis), acute otitis media (AOM), myringotomies and hospitalised 
pneumonia. These were measured by reduction in the disease cases and their associated 
costs. RESULTS: Preliminary results indicate that PHiD-CV could prevent annually 
and for all ages 4.352 hospitalisations (272 meningitis, 2.013 bacteraemia/sepsis and 
2.067 pneumonias), 2.964 myringotomies and 180.361 ambulatory GP-visits for 
AOM, overall reducing disease costs in a34.2M, mainly due to less AOM costs 
(a15.1M). Implementation of PHiD-CV could be a cost-effective intervention com-
pared with no vaccination expressed as cost per QALY gained of a18,597. CONCLU-
SIONS: The analysis predicts that vaccination with PHiD-CV could produce a 
signiﬁcant health improvement and substantial disease cost offset from the National 
Health System perspective when compared to no vaccination. Results support that 
the implementation of PHiD-CV UMV should be considered by Public Health 
decision-makers.
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OBJECTIVES: To compare the cost and efﬁcacy of ritonavir-boosted darunavir 
(darunavir/r) 800/100 mg QD-based triple therapy with combination therapies using 
other boosted protease inhibitors (PI/rs) currently licensed for use in treatment-naïve, 
HIV-1-infected adults in Germany. METHODS: Efﬁcacy was measured by the per-
centage of individuals with plasma HIV RNA  50 copies/mL (the current therapy 
goal) at 48 weeks, based on a systematic review and meta-analysis of clinical trials of 
PI/r-based regimens in treatment-naïve populations. For each PI/r, one-year antiretro-
viral therapy costs (May 2009 Lauer Taxe) were plotted against 48-week efﬁcacy. An 
efﬁciency frontier was constructed by connecting the most economically efﬁcient PI/r-
based regimens. The base-case analysis considered PI/rs with tenofovir-based back-
bone regimens; abacavir-based backbones were considered in scenario analysis. 
RESULTS: In the base-case analysis, darunavir/r was the most efﬁcacious PI/r, with 
an incremental cost-efﬁcacy ratio (ICER) of a20,322 per additional individual with 
virologic response, compared to fosamprenavir/r, the only other point on the efﬁciency 
frontier of PI/r-based initial therapy. All other PI/rs were less efﬁcacious and more 
costly than darunavir/r or fosamprenavir/r, including the two most commonly pre-
scribed PI/rs: atazanavir/r and lopinavir/r. Before the introduction of darunavir/r, 
atazanavir/r was most efﬁcacious but with a higher ICER of a34,244 versus fosam-
prenavir/r. Darunavir/r had an average cost of a20,036 per individual with virologic 
response, compared with a20,976 and a22,861 for atazanavir/r and lopinavir/r, 
respectively. Given a ﬁxed budget of a10 million, darunavir/r successfully treated 499 
individuals, compared with 477 and 437 for atazanavir/r and lopinavir/r, respectively. 
Similar results were obtained in scenario analysis using abacavir-based backbones. 
CONCLUSIONS: Darunavir/r 800/100 mg QD has a lower cost per individual with 
virologic response after 48 weeks than the two most commonly prescribed PI/rs in 
treatment-naïve, HIV-1-infected adults and provides more beneﬁt per additional cost 
than other PI/rs currently used in this population in Germany.
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OBJECTIVES: inﬂuenza vaccination has proven effective in the reduction of inﬂuenza-
like illness (ILI) cases and inﬂuenza-related hospitalisations, drug consumption, 
primary care consultations and deaths in the elderly population. The aim of this study 
is to assess the economic impact in Italy of different prophylactic strategies (vaccina-
tion with a standard vaccine and with the innovative MF59® adjuvated vaccine versus 
no intervention). METHODS: A pharmacoeconomic simulation model has been devel-      
oped. Health economics and demographic data are taken from speciﬁc Italian sources 
and vaccine effectiveness data derived from published. Direct sanitary costs are con-
sidered according to current Italian prices and tariffs. RESULTS: A total of 9,800,000 
of the about 12,000,000 people of 65 years residence in Italy can be considered at 
high risk for inﬂuenza complications due to underlying chronic diseases. Absence of 
vaccination could lead to more than 2 million ILI cases, and 30,000 related deaths. 
The vaccination programme would lead to an estimated 1.5 million ILI cases with a 
standard vaccine and to 1.3 million with the MF59® adjuvated vaccine. The standard 
vaccination strategy could produce a moderate direct cost increase of about a45 
million (4.3%), whereas the adjuvated vaccine could provide an estimated saving of 
about a80 million (7.9%), both compared to the null option. Cost savings are mainly 
related to hospital admissions avoided. The incremental cost-effectiveness ratio (ICER) 
of the standard vaccine vs. no vaccination strategy is of a85.68/ILI avoided, and of 
a4,411.42/death avoided. The strategy based on the MF59® adjuvated vaccine domi-
nates the other two options. CONCLUSIONS: Vaccination with the MF59   ® adjuvated 
vaccine is more effective and cost saving when compared with the standard vaccination 
or no vaccination, thus representing the optimal strategy for the elderly population. 
The standard vaccine, even though a light cost increase, proved to be cost effective 
compared to the null option.
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OBJECTIVES: Comparing the cost-effectiveness of Micafungin (MICA) and Caspo-
fungin (CASPO) for the treatment of systemic candida infections (SCIs) (including 
invasive candidiasis and candidaemia) in Germany. METHODS: A health economic 
decision model is based on a clinical study with a global population. The study was 
a Phase 3 double blind randomized controlled trial comparing MICA versus CASPO. 
Furthermore, German hospitalization and primary medication costs were included in 
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the analysis. The model’s effectiveness outcome is deﬁned as patients who are success-
fully treated and are alive. Cost-effectiveness is measured as total costs per patient 
with respect to effectiveness for each medication arm. In addition, sensitivity analyses 
were performed to identify cost-effectiveness for different clinical and economic 
assumptions. RESULTS: The analysis shows that 60% of MICA patients were suc-
cessfully treated and survived at the end of study compared to 58% of CASPO 
patients. Furthermore, the costs of a MICA treatment (a37,212) are below the costs 
of a CASPO treatment (a37,720). Therefore, the cost-effectiveness ratio is lower for 
MICA (a62,377) than for CASPO (a65,565). This result also holds for all but one of 
the sensitivity analyses. However, probabilistic sensitivity and subgroup analyses show 
that differences cannot be considered statistically signiﬁcant due to large variance. For 
European patients only, who can be assumed to be a more homogenous group and a 
better approximation of German patients, cost-effectiveness ratio for MICA is 59,406 
a compared to a68,217 for CASPO, the difference being statistically signiﬁcant. 
CONCLUSIONS: This study analyzes the cost-effectiveness of MICA as compared to 
CASPO for the treatment of systemic candida infections in Germany. Both lower costs 
and higher effectiveness of MICA render MICA as more cost-effective than CASPO.
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OBJECTIVES: To establish a cost-effective intravenous antibiotic therapy in the treat-
ment of Infective Endocarditis and Bacteremia. METHODS: A cost-effectiveness study 
was performed considering the expenses and use of resources of Mexican Public Health 
Institutions. The study was based on a decision tree with Bayesian approach deﬁning 
three different health states: clinical success (within short or long hospital stay frame), 
therapeutic failure, and death. The alternatives compared were: a) i.v. Vancomycin 
(VAN) as a ﬁrst-line antibiotic therapy followed by a second-line antibiotic therapy 
in therapeutic failure, or b) i.v. Daptomycin (DAP) as a ﬁrst-line or second-line anti-
biotic therapy. The most recent published data concerning efﬁcacies, length of hospital 
stay and adverse events were included in the study. Results were evaluated with 
incremental analysis and one-way sensitivity analysis of most uncertain variables. 
RESULTS: The use of i.v. Daptomycin as ﬁrst-line antibiotic therapy represents savings 
of US$4,619.00 per patient reaching clinical success (CS) when compared to the use 
of i.v. Vancomycin as ﬁrst-line antibiotic therapy (DAP-VAN: US$21,168.00/CS; 
VAN-2nd line antibiotic: US$25,787.00/CS). A greater proportion of patients are more 
likely to attain clinical success when DAP is used as ﬁrst-line antibiotic therapy (DAP-
VAN: 62%; VAN-2nd line antibiotic: 54%) due to a less frequent development of 
adverse events compared to the use of VAN. The sensitivity analysis varying clinical 
success rates of every evaluated alternative demonstrated the robustness of the base 
study. CONCLUSIONS: Daptomycin is the most cost-effective alternative in the treat-
ment of Infective Endocarditis and Bacteremia when used as ﬁrst-line antibiotic therapy 
since it decreases hospital expenses due to a reduced hospital stay and results in a 
greater proportion of patients reaching clinical success. The use of Vancomycin in 
long term treatments is associated with a higher frequency of adverse events which 
can cause treatment interruption resulting in therapeutic failure.
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OBJECTIVES: To estimate the impact of the use of more detailed direct medical costs 
for the economic evaluations (EEs) of universal vaccinations against rotavirus and 
varicella in Brazil on the incremental cost-effectiveness ratios (ICERs). METHODS: 
Previous published EEs were used as basis and new direct medical costs estimates for 
rotavirus and varicella were developed, with the inclusion of speciﬁc costs of the private 
health care system (HCS) for the two diseases, inclusion of public participation for 
dispensing drugs in the case of rotavirus and inclusion of drugs costs in the public HCS 
in the case of varicella. Cost estimate methods consisted of gross-costing and micro-
costing. Data were obtained from national regulatory agency database (ANS), house-
hold survey (PNAD), private (CBHPM, TUNEP) and public (Ministry of Health) 
reference lists. Direct medical costs were then applied to the previous models, preserv-
ing non-medical direct and indirect costs, all costs in 2004 Reals. ICERs were recalcu-
lated and compared to the original calculations, from the HCS and societal perspective. 
Univariate sensitivity analysis was performed to each cost item and discount rate to 
analyse individual impact on ICER. RESULTS: From the societal perspective, there 
was an estimated disease total cost increase of 16% for rotavirus and 11% for varicella, 
as well as increase of savings with the vaccination of 18% and 16%, respectively. 
ICERs were reduced by 20% for rotavirus (to a292/LYS) and 4% for varicella (to 
a4098/LYS), still below the threshold (3xGDP per capita). Sensitivity analysis indicated 
that EEs of vaccination against rotavirus and varicella were more sensitive to the vac-
cination program cost estimates, especially the vaccine price. CONCLUSIONS: 
Although the more detailed cost estimates reduced the ICERs, the level of cost-effective-
ness of the two vaccination programs remained the same. Sensitivity analysis pointed 
out the relevance of the vaccine cost comparatively to the direct medical costs.
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OBJECTIVES: Standard treatment for hepatitis C is peginterferon (PEG-IFN)  RBV 
with the aim of achieving a sustained-virological-response (SVR), which is widely 
considered to be a cure. Around 50% of patients infected with G1 do not achieve 
an SVR but re-treatment with PEG-IFN  RBV is successful in some, especially in 
those who achieve a complete-early-virological-response (HCV-RNA undetectable 
by week 12 [cEVR]). The objective of this analysis was to determine the cost-effective-
ness of re-treating previous G1-non-responders to PEG-IFN  RBV. METHODS: 
A published Markov-model compared three strategies: PEG-IFNA2a  RBV, for 72 
weeks (A), 48 weeks (B) or no treatment (C). Efﬁcacy data for (A) and (B) were taken 
from the REPEAT study, where a difﬁcult-to-treat population of G1-patients with 
previous non-response to PEG-IFN/RBV was investigated. Rates of cEVR were 15% 
for (A) and 9% for (B); SVR rates: 13% for (A) and 7% for (B); rates for (C) assumed 
to be zero. Patients not achieving a cEVR were assumed to discontinue treatment. 
A UK health care payor perspective was adopted. Drug and other costs were taken 
from published sources. A lifetime-horizon was chosen. Incremental-cost-effectiveness-
ratios were expressed as cost per quality-adjusted-life-year (QALY). Costs and QALYs 
were discounted at 3.5% p.a. Sensitivity-analyses were performed. RESULTS: 
The analysis showed that an additional SVR prevented future costs and increased 
quality-adjusted-life-expectancy. Although (A) caused the highest overall drug costs, 
total costs were only £606 higher compared to (B) and £1949 compared to (C), 
reﬂecting the higher SVR rates and the substantial medical costs for patients without 
an SVR. The ICER of (A) vs. (B) was estimated at £2,012/QALY and £2,988/QALY 
for (A) vs. (C). CONCLUSIONS: Re-treatment with PEG-IFNA2a  RBV for 72 weeks 
is a highly cost-effective treatment option for patients not responding to previous 
treatment with PEG-IFN  RBV, regardless of comparator, due to reduction of 
the high medical costs associated with progressive liver disease and the associated 
QALY gains.
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OBJECTIVES: The 7-valent pneumococcal conjugate vaccine (PCV7) and 23-valent 
pneumococcal polysaccharide vaccine (PPV23) are currently recommended for child-
hood and adult vaccination respectively in the UK. A 13-valent pneumococcal conju-
gate vaccine (PCV13) is currently being reviewed by regulatory authorities for use in 
infants and young children, and a clinical development plan for adults is ongoing. 
This study assessed cost-effectiveness of PCV13 compared to the current vaccination 
strategy and to PCV7 given to children alone. METHODS: A steady state, static 
cohort model was constructed comparing PCV13 vaccination of the birth cohort and 
of 65-year old adults with the current strategy and with PCV7 in children alone. The 
model con sidered the incidence and subsequent costs of four infections: pneumococcal 
meningitis; pneumococcal bacteraemia; all cause pneumonia and acute otitis media 
(AOM). Vaccination was assumed to have effects on vaccinated individuals and to 
impact unvaccinated individuals as a result of herd immunity. The number of cases 
and subsequent costs that would occur were estimated in the different scenarios. Sen-
sitivity analysis considered incidence, mortality rates, vaccine efﬁcacy, serotype cover, 
costs, discount rate, uptake and herd immunity. RESULTS: The model estimated that, 
compared to the current strategy (and compared to PCV7 alone), PCV13 would reduce 
the annual incidence of bacteraemia and meningitis by 1176 (1303) cases, prevent 35 
(40) deaths, increase life years by 619 (666), increase QALYs by 694 (731) and reduce 
medical costs by £2.9m (£11.1m). Results are sensitive to vaccine effects against 
pneumonia and the disease incidence in non-vaccinated individuals. CONCLUSIONS: 
Paediatric and adult PCV13 vaccination in the UK was estimated to reduce the burden 
of pneumococcal disease and save costs compared with either the current vaccination 
strategy or a paediatric PCV7 only strategy. Final cost-effectiveness will depend on 
the emergence of herd immunity beneﬁts in the UK, impact on pneumonia, vaccine 
schedule and price.
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OBJECTIVES: To determine the cost-effectiveness of the protocol of the international          
‘Surviving Sepsis Campaign’ (SSC) for the treatment of severe sepsis in Spain after the 
implementation of a multicentre educational program compared with the conventional 
